[Federal Register Volume 87, Number 166 (Monday, August 29, 2022)]
[Proposed Rules]
[Page 52712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18729]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA824]


Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-
iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in 
Schedule I; Withdrawal of Proposed Rule

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Withdrawal of proposed rule.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is withdrawing a 
proposed rule that was published in the Federal Register on April 11, 
2022, which proposed to place two phenethylamine hallucinogens in 
schedule I of the Controlled Substances Act. DEA is withdrawing the 
proposed rule, terminating all proceedings related thereto, and will be 
publishing a new proposed rule using an amended procedure.

DATES: The proposed rule that was published in the Federal Register on 
April 11, 2022 (87 FR 21069), is withdrawn as of August 25, 2022, and 
all proceedings related thereto are terminated.

FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Chief, Drug 
and Chemical Evaluation Section, Diversion Control Division, Drug 
Enforcement Administration; Mailing Address: 8701 Morrissette Drive, 
Springfield, Virginia 22152; Telephone: (571) 362-3249.

SUPPLEMENTARY INFORMATION: On April 11, 2022, the Drug Enforcement 
Administration (DEA) published a Notice of Proposed Rulemaking (NPRM) 
in the Federal Register (87 FR 21069) to place two phenethylamine 
hallucinogens--specifically, 2,5-dimethoxy-4-iodoamphetamine (DOI), and 
2,5-dimethoxy-4-chloroamphetamine (DOC)--in schedule I of the 
Controlled Substances Act (CSA) (21 U.S.C. 801, et seq.).
    DEA has determined that it is appropriate to withdraw the proposed 
rule published in the Federal Register on April 11, 2022 (87 FR 21069), 
and to terminate all proceedings related thereto. DEA is planning to 
publish a new proposed rule with an amended procedure.

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
August 25, 2022, by Administrator Anne Milgram. That document with the 
original signature and date is maintained by DEA. For administrative 
purposes only, and in compliance with requirements of the Office of the 
Federal Register, the undersigned DEA Federal Register Liaison Officer 
has been authorized to sign and submit the document in electronic 
format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2022-18729 Filed 8-26-22; 8:45 am]
BILLING CODE 4410-09-P